Jemperli
What Jemperli is used for
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Jemperli
- Active substance
- dostarlimab
- Disease area
- Endometrial Neoplasms
- Medicine group
- Antineoplastic Agents and Antibody Drug Conjugates
- ATC code
- L01FF07
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Jemperli
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jemperli used for?
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
What is the active substance in Jemperli?
Jemperli contains dostarlimab.
Who makes Jemperli?
The EU marketing authorisation holder is GlaxoSmithKline Trading Services Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU